Jacquelyn L. Sumer - 30 Jun 2026 Form 4 Insider Report for Cullinan Therapeutics, Inc. (CGEM)

Reporting relationship: Chief Legal Officer
Issuer ticker: CGEM
Reported as of: 30 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Jul 2026, 17:00:36 UTC
Prior SEC filing: 25 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Jacquelyn Sumer

Key filing fact

Jacquelyn L. Sumer filed Form 4 for Cullinan Therapeutics, Inc. (CGEM) on 02 Jul 2026.

Key facts

This page summarizes Jacquelyn L. Sumer's Form 4 filing for Cullinan Therapeutics, Inc. (CGEM).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 02 Jul 2026, 17:00.

Change

Previous filing in this sequence was filed on 25 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001844824 Primary reporting owner

SUMER JACQUELYN L

Relationship: Chief Legal Officer
Address: C/O CULLINAN THERAPEUTICS, INC., ONE MAIN STREET, SUITE 1350, CAMBRIDGE
Signature: /s/ Jacquelyn Sumer
Signature date: 02 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CGEM transaction

Common Stock

Award

Transaction value
Shares: +2,470
Change %: +1.9%
Price: $8.60^*
Shares after: 130,559
Date: 30 Jun 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Issuer's 2021 Employee Stock Purchase Plan (the "ESPP"), for the purchase period of January 1, 2026 through June 30, 2026. This transaction is also exempt under Rule 16b-3(c).

Footnote F2

In accordance with the ESPP, the shares were purchased based on 85% of the closing price of the Issuer's common stock on January 2, 2026.